idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an
Company profile
Ticker
IDXX
Exchange
Website
CEO
Jonathan Jay Mazelsky
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
342 Saco Street, LLC • Beijing IDEXX Laboratories Co. Limited • ezyVet US, Inc. • IDEXX Animana B.V. • IDEXX Brasil Laboratórios Ltda. • IDEXX Brasil Participações Ltda. • IDEXX Diagnostic Limited • IDEXX Diavet AG • IDEXX Distribution, Inc. • IDEXX GmbH ...
IRS number
10393723
IDXX stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
27 Mar 24
DEFA14A
Additional proxy soliciting materials
27 Mar 24
DEF 14A
Definitive proxy
27 Mar 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Results of Operations and Financial Condition
5 Feb 24
8-K
Departure of Directors or Certain Officers
7 Dec 23
10-Q
2023 Q3
Quarterly report
1 Nov 23
8-K
Results of Operations and Financial Condition
1 Nov 23
10-Q
2023 Q2
Quarterly report
1 Aug 23
8-K
Results of Operations and Financial Condition
1 Aug 23
Transcripts
IDXX
Earnings call transcript
2023 Q4
5 Feb 24
IDXX
Earnings call transcript
2023 Q3
1 Nov 23
IDXX
Earnings call transcript
2023 Q2
1 Aug 23
IDXX
Earnings call transcript
2023 Q1
2 May 23
IDXX
Earnings call transcript
2022 Q4
6 Feb 23
IDXX
Earnings call transcript
2022 Q3
1 Nov 22
IDXX
Earnings call transcript
2022 Q2
2 Aug 22
IDXX
Earnings call transcript
2022 Q1
4 May 22
IDXX
Earnings call transcript
2021 Q4
2 Feb 22
IDXX
Earnings call transcript
2021 Q3
2 Nov 21
Latest ownership filings
4
JAMES F POLEWACZYK
7 Mar 24
4
Sophie V. Vandebroek
7 Mar 24
144
Notice of proposed sale of securities
6 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
4
JONATHAN JAY MAZELSKY
4 Mar 24
4
JONATHAN JAY MAZELSKY
22 Feb 24
4
Sharon E. Underberg
20 Feb 24
4
BRIAN P MCKEON
20 Feb 24
4
Sharon E. Underberg
16 Feb 24
4
Martin Alexander Smith
16 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
86.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1020 |
Opened positions | 103 |
Closed positions | 96 |
Increased positions | 362 |
Reduced positions | 362 |
13F shares | Current |
---|---|
Total value | 31.47 tn |
Total shares | 72.01 mm |
Total puts | 174.40 k |
Total calls | 160.80 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 8.63 mm | $3.78 tn |
Vanguard | 8.26 mm | $3.61 tn |
STT State Street | 3.76 mm | $1.65 tn |
Alliancebernstein | 3.33 mm | $1.45 tn |
Fundsmith | 2.96 mm | $1.30 tn |
Bamco | 2.34 mm | $1.02 tn |
Geode Capital Management | 2.06 mm | $901.10 bn |
BEN Franklin Resources | 1.38 mm | $602.27 bn |
IVZ Invesco | 1.22 mm | $532.15 bn |
Blair William & Co | 1.20 mm | $524.70 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Mar 24 | James F Polewaczyk | Common Stock | Sell | Dispose S | No | No | 559.3318 | 680 | 380.35 k | 10,711.235 |
6 Mar 24 | James F Polewaczyk | Common Stock | Sell | Dispose S | No | No | 558.8822 | 3,290 | 1.84 mm | 11,391.235 |
6 Mar 24 | James F Polewaczyk | Common Stock | Sell | Dispose S | No | No | 557.941 | 4,134 | 2.31 mm | 14,681.235 |
6 Mar 24 | James F Polewaczyk | Common Stock | Option exercise | Acquire M | No | No | 544.08 | 4,640 | 2.52 mm | 18,815.235 |
6 Mar 24 | James F Polewaczyk | Common Stock | Option exercise | Acquire M | No | No | 288.78 | 2,226 | 642.82 k | 14,175.235 |
6 Mar 24 | James F Polewaczyk | Common Stock | Option exercise | Acquire M | No | No | 206.94 | 483 | 99.95 k | 11,949.235 |
6 Mar 24 | James F Polewaczyk | Common Stock | Option exercise | Acquire M | No | No | 206.94 | 755 | 156.24 k | 11,466.235 |
6 Mar 24 | James F Polewaczyk | NQSO Common Stock | Option exercise | Dispose M | No | No | 544.08 | 4,640 | 2.52 mm | 1,363 |
6 Mar 24 | James F Polewaczyk | NQSO Common Stock | Option exercise | Dispose M | No | No | 288.78 | 2,226 | 642.82 k | 0 |
6 Mar 24 | James F Polewaczyk | Incentive Stock Option (right-to-buy) Common Stock | Option exercise | Dispose M | No | No | 206.94 | 483 | 99.95 k | 0 |
News
West Pharmaceutical Q1 Earnings Beat, HVP Sales Weak
25 Apr 24
$1000 Invested In IDEXX Laboratories 10 Years Ago Would Be Worth This Much Today
16 Apr 24
Here's How Much You Would Have Made Owning IDEXX Laboratories Stock In The Last 20 Years
27 Mar 24
$100 Invested In IDEXX Laboratories 5 Years Ago Would Be Worth This Much Today
11 Mar 24
Here's How Much $1000 Invested In IDEXX Laboratories 15 Years Ago Would Be Worth Today
27 Feb 24
Press releases
IDEXX Laboratories to Release 2024 First Quarter Financial Results
4 Apr 24
IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences
20 Feb 24
IDEXX Launches Vello™, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect
15 Feb 24
IDEXX Announces Fourth Quarter and Full Year Results
5 Feb 24